AUTOLOGOUS MARROW TRANSPLANTATION FOR MULTIPLE MYELEMAL

多发性骨髓瘤的自体骨髓移植

• 批准号: 3817224
• 负责人: WILLIAM BENSINGER
• 金额: --
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3817224
• 关键词: autologous transplantation; bone marrow transplantation; busulfan; complement; cyclophosphamide; drug adverse effect; hematopoietic stem cells; human subject; human therapy evaluation; monoclonal antibody; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer therapy; prednisone

This project will evaluate autologous marrow transplantation for patients with multiple myeloma. Initial studies will utilize a regimen of busulfan and cyclophosphamide with unpurged marrow to determine toxicity of the regimen, and repopulating ability of the marrow. In vitro studies will evaluate the efficacy of several different techniques for marrow purging including prednisone, monoclonal antibodies with complement and positive selection of hematopoietic precursor cells. Subsequent, clinical studies will evaluate engraftment using the most promising marrow purging technique. Future studies will explore different treatment regimens and transplantation earlier in the disease course with the ultimate goal of developing curative strategies.

该项目将对自体骨髓移植进行评估 多发性骨髓瘤患者。初步研究将利用 白花丹联合环磷酰胺联合未净化骨髓治疗 确定该方案的毒性，并确定其再繁殖能力 骨髓。体外研究将评估几种药物的疗效 不同的骨髓净化技术包括泼尼松， 具有补体和阳性选择的单抗 造血祖细胞。随后的临床研究将 使用最有希望的骨髓净化方法评估植入 技术。未来的研究将探索不同的治疗方法 在疾病病程的早期进行方案和移植 制定治疗策略的最终目标。